Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ANPEP | P15144 | 3/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11207354 | 0.96 | ALDH1A1 (0.56) | ALDH1A1ANPEPFOLH1ATMTLR2 | |
| SCHEMBL8853611 | 0.96 | ALDH1A1 (0.56) | ALDH1A1ANPEPFOLH1ATMTLR2 | |
| SCHEMBL8088658 | 0.85 | ALDH1A1 (0.63) | ALDH1A1ANPEPATM | |
| SCHEMBL4599998 | 0.84 | CPB2 (0.53) | ALDH1A1ANPEPFOLH1ATMTLR2 | |
| SCHEMBL4600004 | 0.84 | CPB2 (0.53) | ALDH1A1ANPEPFOLH1ATMTLR2 | |
| SCHEMBL4599358 | 0.84 | CPB2 (0.67) | ALDH1A1FOLH1CPB2 | |
| SCHEMBL4599368 | 0.84 | CPB2 (0.67) | ALDH1A1FOLH1CPB2 | |
| SCHEMBL4599834 | 0.84 | CPB2 (0.67) | ALDH1A1FOLH1CPB2 | |
| SCHEMBL2722853 | 0.83 | ALDH1A1 (0.58) | ALDH1A1ANPEPFOLH1ATM | |
| SCHEMBL13559295 | 0.82 | NAALAD2 (0.71) | ALDH1A1ANPEPFOLH1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149262-A1 | Benzodiazepine vitronectin receptor antagonist pharmaceuticals | CHEESMAN EDWARD H (US) | 2003-08-07 | — | — | US | claimed |
| US-20030149262-A1 | Benzodiazepine vitronectin receptor antagonist pharmaceuticals | CHEESMAN EDWARD H (US) | 2003-08-07 | — | — | US | disclosed |
| US-6548663-B1 | Imaging tumors and cancer with radioisotope benzodiazepine metal complex as contrast agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149262-A1 | Benzodiazepine vitronectin receptor antagonist pharmaceuticals | ADGRF1, GPR174, NPSR1 | ALDH1A1 2856/4885ANPEP 903/4885FOLH1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.